Chinook Therapeutics (NASDAQ:KDNY) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Chinook Therapeutics and Intra-Cellular Therapies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Chinook Therapeutics | 0 | 0 | 8 | 0 | 3.00 |
| Intra-Cellular Therapies | 0 | 0 | 7 | 0 | 3.00 |
Chinook Therapeutics presently has a consensus price target of $30.3333, suggesting a potential upside of 90.78%. Intra-Cellular Therapies has a consensus price target of $47.4286, suggesting a potential upside of 51.92%. Given Chinook Therapeutics' higher probable upside, research analysts clearly believe Chinook Therapeutics is more favorable than Intra-Cellular Therapies.
Valuation & Earnings
This table compares Chinook Therapeutics and Intra-Cellular Therapies' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Chinook Therapeutics | $17.26 million | 39.04 | $-82,370,000.00 | ($5.15) | -3.09 |
| Intra-Cellular Therapies | $60,000.00 | 42,103.81 | $-147,720,000.00 | ($2.68) | -11.65 |
Chinook Therapeutics has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Chinook Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Chinook Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.
Insider and Institutional Ownership
79.1% of Intra-Cellular Therapies shares are held by institutional investors. 5.9% of Chinook Therapeutics shares are held by insiders. Comparatively, 18.2% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Chinook Therapeutics and Intra-Cellular Therapies' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Chinook Therapeutics | -215.80% | -112.72% | -21.36% |
| Intra-Cellular Therapies | -1,985.32% | -48.27% | -42.56% |
Summary
Chinook Therapeutics beats Intra-Cellular Therapies on 7 of the 13 factors compared between the two stocks.
